Belhaven Biopharma | Finanzwire

Basculer en Français

10097	Companies
206690	Keywords
136846	Articles
109549	Press releases

Home
Companies
Belhaven Biopharma

BRIEF

published on 07/09/2024 at 17:05, 1 year 8 months ago

Belhaven Biopharma Study Shows Promising Results for Nasal Epinephrine Delivery

Belhaven Biopharma Nasdepi Anaphylaxis Treatment Medical Research Nasal Epinephrine
PRESS RELEASE

published on 07/09/2024 at 17:00, 1 year 8 months ago

New Canine Study From Belhaven Biopharma Supports Dry Powder Nasal Epinephrine Delivery Solution
Belhaven Biopharma presents promising results of Nasdepi Canine Study at Respiratory Drug Delivery 2024, indicating faster & effective treatment for anaphylaxis. Intranasal dry powder epinephrine offers breakthrough prospects in emergency care for severe allergies

Belhaven Biopharma Anaphylaxis Treatment Nasdepi Canine Study Dry Powder Nasal Solution Respiratory Drug Delivery 2024
PRESS RELEASE

published on 02/08/2024 at 18:30, 2 years 1 month ago

Belhaven Biopharma Announces Groundbreaking Clinical Results for Nasdepi, the Revolutionary Nasal Dry Powder Epinephrine Product
Belhaven Biopharma shares positive results from Phase 1 clinical trial of Nasdepi, a nasal dry powder epinephrine device for treating anaphylaxis. Successful investor round and Series A financing on the horizon

Phase 1 Clinical Trial Series A Financing Belhaven Biopharma Nasdepi Anaphylaxis Treatment
PRESS RELEASE

published on 11/28/2023 at 19:30, 2 years 3 months ago

Belhaven Biopharma Achieves Significant Milestones in Advancing Nasdepi - a Revolutionary Nasal Dry Powder Epinephrine Product

Accesswire

Published on 03/26/2026 at 11:07, 26 minutes ago

U.S. Mined and Refined Metals as well as Rare Earth Elements to Be Tokenized in Historic American Strategic Minerals and Datavault AI Deal
Published on 03/26/2026 at 11:00, 33 minutes ago

Pivotree Announces Fourth Quarter 2025 Results
Published on 03/26/2026 at 11:00, 33 minutes ago

Stagwell Expands the Harris Poll's Harrisquest Across Europe
Published on 03/26/2026 at 08:05, 3 hours 28 minutes ago

Vanta Announces U.S. Ticker Symbol Change to VNTXF
Published on 03/26/2026 at 04:55, 6 hours 38 minutes ago

Vanta Announces Capital Markets Initiatives to Strengthen Financial Position and Support Growth Initiatives

View all ACCESSWIRE

EQS Group

Published on 03/26/2026 at 11:03, 30 minutes ago

EQS-Adhoc: VIDINEXT AG: Marketing agreement with Telekom Deutschland GmbH
Published on 03/26/2026 at 11:00, 33 minutes ago

Genel Energy PLC: Posting of Annual Report and Notice of AGM
Published on 03/26/2026 at 11:00, 33 minutes ago

Genel Energy PLC: Report on payments to governments for the year 2025
Published on 03/26/2026 at 11:00, 33 minutes ago

ABB Ltd: ABB share buybacks - March 19, 2026 - March 25, 2026
Published on 03/26/2026 at 11:00, 33 minutes ago

Independent study reveals 44% ROI with EQS Compliance Cockpit and payback in under six months

Les Echos

Published on 03/26/2026 at 08:57, 2 hours 35 minutes ago

Edenred statement
Published on 03/26/2026 at 07:30, 4 hours 3 minutes ago

BIOPHYTIS-LYNXKITE ALLIANCE INVITED TO NVIDIA CONFERENCE: UNLEASHING AI TO REVOLUTIONIZE LONGEVITY
Published on 03/25/2026 at 18:53, 16 hours 39 minutes ago

LNA SANTE : 2025 Annual Results
Published on 03/25/2026 at 18:31, 17 hours 2 minutes ago

Strong investment performance and active roll-out of our strategy
Published on 03/25/2026 at 17:45, 17 hours 48 minutes ago

Combined General Meeting on May 05, 2026: publication of the notice of Meeting

View all LES ECHOS COMFI WIRE